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Abstract: Epilepsy is a central neurological disorder affecting individuals of all ages and causing
unpredictable seizures. In spite of the improved efficacy of new antiepileptic drugs and novel therapy,
there are still approximately 20%~30% of patients, who have either intractable or uncontrolled
seizures. The epilepsy drug–target network (EDT) is constructed and successfully demonstrates the
characteristics and efficacy of popularly used AEDs through the identification of causative genes for
60 epilepsy patients. We discovered that the causative genes of most intractable patients were not the
targets of existing AEDs, as well as being very far from the etiological mechanisms of existing AEDs
in the functional networks. We show that the existence of new drugs that target the causative genes of
intractable epilepsy patients, which will be potential candidates for refractory epilepsy patients. Our
systematic approach demonstrates a new possibility for drug repositioning through the combination
of the drug-target and functional networks.
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1. Introduction
Epilepsy is the most common neurological disorder with heterogeneous causes, affecting 1%~2%
of the population. The majority of patients with epilepsy can be effectively treated, given an accurate
diagnosis and appropriate medication. In order to select efficientdrug regimens, accurate diagnosis for
the types of epilepsy is very critical [1,2], and the goal of epilepsy management is complete control
of seizures with little or no adverse effects from the appropriate antiepileptic drug (AED). However,
most of the existing therapies for epilepsy patients have focused on symptomatic treatment with such
drugs instead of identifying the leading cause of epilepsy. There are general sorted antiepileptic drug
lines of treatment for specific types of epilepsy [3,4]. If a single drug cannot control the seizure, then a
combination of several AED [5–7] is provided, or a ketogenic diet is recommended [8–12]. In spite of
the improved efficacy of new AED drugs and novel therapies, there still approximately 20%~30% of
patients who have either intractable or uncontrolled seizures [13,14].
A recent improvement in the cost and accuracy of whole-exome sequencing (WES) has enabled
the accurate diagnosis of genetic diseases and the identification of the causative variants of epilepsy
patients. Especially for patients with refractory epilepsy, WES is popularly used to identify accurate
causative genes through the trio analyses, which would be very helpful in providing an accurate
diagnosis of epilepsy patients with unknown origin. The understanding of biological mechanisms of
existing AEDs and pathologies of epilepsies can lead to a dramatic advance of AED development. Thus,
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it is a feasible strategy to predict appropriate drugs based on the causative genes or perturbed biological
pathways of refractory epilepsy patients, which shows the great impact of precise medicine [15–19].
In this study, we construct the epilepsy drug–target network (EDT) and successfully demonstrate
the characteristics and effectiveness of popularly used AEDs and the pathological mechanisms of
existing AEDs. Especially, we discovered that the causative genes of most intractable patients were not
the targets of existing AEDs, as well as that they are located far from the etiological mechanisms of
existing AEDs in the functional networks. Finally, we show the existence of new potential drugs, which
target the causative genes of intractable epilepsy patients, which will be a new candidate for refractory
epilepsy patients. Our systematic approach demonstrates a new possibility for drug repositioning
through the combination of the drug-target and functional networks.
2. Materials and Methods
2.1. Clinical Exome Sequencing and Data Analysis
We utilized the TruSight One sequencing panel providing comprehensive coverage of <4800
clinically known disease-associated genes. Sequencing was performed using the Illumina MiSeq. The
sequenced reads were mapped to the human reference (UCSC hg19) with the Burrows-Wheeler aligner
(BWA), and variants were identified with the genome analysis toolkit (GATK). Sequence variants were
filtered according to various quality parameters. The segregation of the pathogenic mutation in the
family was verified by automatic Sanger sequencing using the BigDye (Applied Biosystems, v3.1,
Foster City, CA, USA) protocol on a 3130 XL analyzer (Applied Biosystems).
2.2. AED Lists
In this study, we focused on 13 popularly used AEDs covering classical AEDs as well as
new AEDs: carbamazepine, phenytoin, valproic acid, ethosuximide, primidone, phenobarbital,
lamotrigine, oxcarbazepine, topiramate, zonisamide, gabapentin, vigabatrin, and levetricacetam.
Note that benzodiazepine and tigabine were excluded due to missing drug-target information in the
DGI Database.
2.3. Disease Causative Genes
GeneCards is a comprehensive database providing information on all annotated and predicted
human genes by integrating genomic, transcriptomic, proteomic, genetic, clinical, and functional
information. We downloaded 2208 epilepsy-associated genes from GeneCards. After filtering out the
genes without EntrezID mapping information, 2116 epilepsy-associated genes are used in this study.
2.4. Drug-Target Interactions (DGIs)
The Drug-Gene Interactions Database (DGIdb, www.dgidb.org) is a resource describing drug–gene
interactions and gene druggability. DGIdb integrated 27 sources describing drug–gene interactions
and druggable gene categories including DrugBank or the Therapeutic Target Database (TTD). We
complied all drugs targeting any of the 2116 epilepsy-causative genes, which led to 2480 drugs. Some
of the ambiguous drug names are filtered out. Among 2116 epilepsy-causative genes, 694 genes are
targeted by current drugs in DGIdb.
2.5. Network Database
The STRING 9.1 network database, one of the largest databases of direct protein–protein
interactions and indirect functional interactions constructed from various data sources, was used.
It contained approximately 20,772 proteins, with 2,425,315 interactions among them. We extracted
the interactions among 2116 epilepsy-causative genes from the STRING protein-protein interaction
(PPI) network, which covers 4815 interactions among them and then filtered out the low-quality
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interactions. Entrez gene IDs were used to map disease-associated genes to the corresponding proteins
and drug targets.
2.6. Construction of EDT-DRUG Network
We constructed a drug-target network covering 2116 epilepsy-causative genes and 13 clinically
used epilepsy drugs and 636 putative drugs targeting any of epilepsy-causative genes and their
interactions (Figure 1). The constructed network was visualized by Cytoscape v3.4.0.
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Figure 1. Data Integration Schema: Data source for drug-target information, epilepsy causative genes,
and protein-protein interaction and their statistics.
3. Results
3.1. Characteristics of Clinically Used Anti-Epileptic Drugs
We collected 13 clinically used anti-epileptic drugs (Table 1) and 2116 genes known to be associated
with epilepsy from the GeneCard database. We integrated the drug-target interaction information
from the DGI database and protein-protein interactions (PPIs) from String databases, which leads the
total of 143 drug-target interactions and 4815 PPIs.
Table 1. Clinically used AED (anti-epileptic drug)
Anti-Epileptic Drug
Name Type Usage/Effects Serious Side Effects
ZONISAMIDE
classical anti-epileptic
drug/broad-s ectrum
AED
used as adjunctive
therapy, indicated for
partial seizures in adults
Ataxis
CARBAMAZEPINE
classical anti-epileptic
drug/narrow-spectrum
AED
decreasing nerve
impulses that cause
seizure and pain,
indicated for temporal
love epilepsy, grand mal
and mixed type s izures
Dermatologic reactions,
bone marrow
suppression
VALPROIC ACID
classical anti-epileptic
drug/broad-spectrum
AED
preventing of absence
seizures, partial seizures,
and generalized seizures
Hepatotoxicity,
pancreatitis, congenital
malformations
PHENOBARBITAL
classical anti-epileptic
drug/narrow-spectrum
AED
slows the activity of the
brain and nervous
system, used for tonic
clonic seizure
CNS depression
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Table 1. Cont.
Anti-Epileptic Drug
Name Type Usage/Effects Serious Side Effects
LAMOTRIGINE
new anti-epileptic
drug/broad-spectrum
AED
used for focal seizures,
tonic-clonic seizures,
Lenox–Gastaut
syndrome
Stevens–Johnson
syndrome
TOPIRAMATE
new anti-epileptic
drug/broad-spectrum
AED
used for generalized
tonic-clonic seizure and
developmental delay
Neuropsychiatric
reactions, visual field
defect
PRIMIDONE classical anti-epilepticdrug
used for grand mal or
focal seizure and
neuropathic pain
Ataxia, vertigo
GABAPENTIN
new anti-epileptic
drug/narrow-spectrum
AED
used for partial seizures
or neuralgia, affects
chemicals and nerves in
the body
Hypersensitivity
LEVETIRACETAM
new anti-epileptic
drug/broad-spectrum
AED
used for partial-onset or
tonic-clonic seizures,
myoclonic seizures
Psychiatric symptoms,
anaphylaxis
PHENYTOIN
classical anti-epileptic
drug/narrow-spectrum
AED
used for status
epilepticus, slow down
impulses in the brain
causing seizures
Hypotension,
arrhythmias
OXCARBAZEPINE
new anti-epileptic
drug/narrow-spectrum
AED
used for partial seizure,
decrease nerve impulses
Hyponatremia,
hypersensitivity
VIGABATRIN
new anti-epileptic
drug/narrow-spectrum
AED
used in combination
with other medicines,
treats for complex partial
seizures
Vision loss
ETHOSUXIMIDE classical anti-epilepticdrug treat absence seizures Allergic reactions
First of all, we focused on highly targeted genes by known anti-epileptic drugs and targeted gene
statistics of current AEDs. As shown in Figure 2, voltage-gated sodium channel-related genes (e.g.,
SCN2A, SCN1A, SCN5A) are remarkably ranked as the highly targeted genes, where approximately
half of clinically used AEDs are designed to target this specific molecular mechanism. Interestingly,
the voltage-gated sodium channels are known to initiate action potentials in brain neurons and are
primary therapeutic targets of AEDs and other neurological disorders. Thus, mutations of genes in
sodium channels are very critical for genetic epilepsy syndromes. Many AEDs are mostly designed
to control this pathological mechanism, which explains the major causes of epilepsy. Our analysis
clearly discovered the fundamental importance of voltage-gated sodium channels in epilepsy. In
addition, CYP2C19 and NR1I2 (i.e., PXR) [20] are also identified as highly targeted genes by clinically
used AEDs. CYP2C19 is a known liver enzyme that acts on 10%~15% of drugs in current clinical
uses. Genetic polymorphism of cytochrome P450 genes, such as CYP2C9 and CYP2C19, is especially
known for drug resistance in epilepsy patients and it may be the reason that such genes are highly
targeted by current AEDs. In addition, the pregnane X receptor (PXR) also plays critical and diverse
roles in mediating xenobiotic induction of drug-metabolizing enzymes and transporters. Our results
effectively demonstrate that such important AED target genes are strongly associated with pathological
mechanisms of epilepsy. To further investigate the characteristic of current AEDs, we showed the
number of targets of current AEDs and their known associations with epilepsy. As shown in Figure 2b,
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traditional AEDs such as zonisamide (26)., carbamazepine, and valproic acid are targeting a relatively
large number of genes, which may lead to the large therapeutic effects but unexpected side effects
due to the broad targeting of genes. Meanwhile, recently developed drugs such as oxcarbazepine,
vigabartrin, and ethosuximide are specially designed to target a relatively small number of genes,
which reduce the side effects and drug interactions, although their therapeutic effects are relatively less
than traditional ones. Clinically, traditional AEDs reveal more severe side effects than relatively newly
developed drugs, which is explained in Figure 2b. In addition, carbamazepine or lamotrigine reveal
that they are also targeting many genes that do not have a known association with epilepsy. One of the
reasons for this difference is that known associations with epilepsy and its causative genes are not
sufficient, or those drugs might play multiple roles for other diseases as well.
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Figure 2. Clinically used anti-epileptic drugs (AED), Targets, and epilepsy-associated genes. (a)Highly
targeted gene by AEDs, the x-axis represents the target genes of 13 clinically used AEDs, the y-axis
represents the number of drugs targeting the genes. CGTG represents that it is an epilepsy-causative
gene as well as a target gene of AEDs, and TG represents that it is only a target gene of AEDs (b)
Target distribution of 13 clinically used AEDs, blue bar represents the number of target genes, red bar
represents the number of epilepsy-associated target genes.
To investigate the relationship between current AED targets and epilepsy-associated genes,
we constructed a drug-target-causative gene network covering AED drug-target interactions and
protein-protein interactions between epilepsy-associated proteins (Figure 3). Interestingly, as we can
see in Figure 3, among a large number of epilepsy causative genes, only a small portion of causative
genes are targeted by current used AEDs. Although most of epilepsy causative genes are not targeted
by current known AEDs, as shown with green nodes in Figure 3, current drugs show fairly enough
therapeutic efficacy to control most of the epilepsy patients. It can be explained by the fact that most
of the epilepsy patients share similar etiological factors and current AEDs could well control such
pathological echanisms without the direct targeting of the specific genes. Thus, most of the epilepsy
patients under control by current AEDs have pathological problems that are effectively controlled
by current AEDs (i.e., yellow nodes in Figure 3), and it reveals evidence for the broad efficacy of
current AEDs. However, in the case of intractable epilepsy patients, causative genes neither have direct
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interactions with the targets of current AEDs nor do they show close proximity with the current targets
of AEDs in the PPI network. Thus, the pathological mechanisms of intractable epilepsy patients cannot
be controlled by the pharmacological mechanisms of current AEDs.
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3.2. Epilepsy Associated Genes and Active Targeting Drug
For 2116 epilepsy causative genes, we extracted all known drugs targeting any of such epilepsy
associated genes, which lead to the 5657 drug–target interactions from DGI database after filtering.
Based on the drugs in DGI databases, 1445 known epilepsy causative genes could not be any of known
drug targets and only 671 genes are currently targeted by at least one of existing drugs, leading to
a total of 2480 drugs and 5657 drug-arget interactions. Interestingly, there are many well-known
drugs targeting epilepsy-associated genes although they are not designed for epilepsy. It shows
the new potential of these drugs for drug-repositioning to epilepsy. Since these drugs have already
been approved for use in humans and we know that they are actually targeting epilepsy causative
genes, they could be very successful candidate drugs for epilepsy patients. Many different drugs with
shared targets could control the same or similar olecular pathways and a drug repositioning strategy
based on target gene proximity is very promising in suggesting new potential drugs especially for
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intractable epilepsy patients. In order to extract the potential candidate epilepsy drugs, we identified
the drugs having more than three epilepsy causative genes as targets, which might be used for further
investigation for drug repositioning to epilepsy (supple 1).
3.3. Identification of Causative Genes from Intractable Epilepsy Patients
Based on our observation, we suspect that the causative genes of such intractable epilepsy patients
are neither connected with targets of current AEDs, nor located close to them. Indeed, most of the
causative genes identified from intractable epilepsy patients are isolated from the target cluster of
current AEDs. For example, the genes associated with voltage-gated potassium channels (e.g., KCNQ1,
KCNQ2, KCNQ3, KCNV1, KCNV2, KCNA1, KCND1, KCNG2) are identified as ones of popular
causative genes from intractable epilepsy patients, as shown in Figure 3. Thus, recently, a burgeoning
number of AEDs has been developed and reported to target voltage-gated potassium channels. It
might be the reason that current available AEDs fails to control for epilepsy patients having problems
in potassium voltage-gated channels.
3.4. Accurate Diagnosis for Epilepsy Patients Through NGS
We observed 60 epilepsy patients who were referred and consented for clinical exome sequencing
at the clinical genetics laboratory of Severance Children’s Hospital. Most epilepsy patients were
effectively controlled by current AEDs. For some of the intractable epilepsy patients (i.e., 16 patients),
ketogenic diet or combination therapy was recommended depending on their manifestations. To
investigate the efficacy of current AEDs, we checked the medical history of 16 patients from EMR
(electronic medical records). With the investigation of the pathogenic mutations of patients and the
efficacy of AEDs, interestingly, we found that epilepsy patients having pathogenic mutations in the
genes associated with voltage-gated sodium channels (i.e., SCN8A, SCN2A) are well controlled with
clinical AEDs without any serious side effects. Note that the voltage-gated channel pathway is one of
the most targeted pathways by current AEDs (Figures 2a and 3), and it may be the reason that patients
having pathogenic mutations in voltage-gated sodium channels are well controlled with current
AEDs. Among these 16 patients with epilepsy, we identified 4 patients who could not be treated with
combination therapy and their pathogenic mutations. Our analysis demonstrated that patients having
pathogenic mutations in MECP2, CDKL5, PRODH, KCNQ2 are not controlled well with existing AEDs,
which lead to the recurrence of epilepsy after therapy with current AEDs (Table 2). We investigated
the causative genes of those intractable epilepsy patients (i.e., MECP2, CDKL5, PRODH, KCNG2) in
our AED-target genes-epilepsy associated gene network. Indeed, these causative genes are not the
direct targets of current AEDs and are also very far from current targets (Figure 3). That explains
the inefficacy of the existing drugs for those intractable epilepsy patients. Furthermore, we may
recommend the new candidate drugs for these intractable epilepsy patients be based on their PPI
interactions in our network.
Table 2. The causative genes of intractable epilepsy patients and representative manifestation.
Patient ID Symptom Identified Causative Genes fromWhole Exome Sequencing
1 Seizure, Rett Syndrome MECP2
2 Epilepsy, West syndrome CDKL5
3 Early infantile epileptic encephalopathy, West syndrome,mental retardation, microcephaly KCNQ2
4
Epilepsy, metabolic disorder, cerebral palsy,
leukodystrophy, mitochondrial myopathy, delayed
development
PRODH
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3.5. NGS for Epilepsy Patients
We identified the number of epilepsy causative genes targeted by epilepsy drugs as well as
putative drugs. Figure 4a shows the statistics of epilepsy causative genes and where how often
they are targeted by currently available drugs. As we can see, among a total of 671 targeted genes,
approximately 216 epilepsy causative genes (32.2%) are targeted by only one specific drug. On the
other hand, about 22 genes were targeted by at least 50 drugs. Note that 4 among those 21 genes
(i.e., HTR2A, CHRM3, HTR1A, HTR2C, and GABRA1) were targeted by over 80 drugs, which shows
their high druggability. Interestingly, the 5-hydroxytryptamine receptor family (e.g., HTR2A, HTR1A,
HTR2C, HTR1B, HTR7, HTR3A, etc) and the gamma-aminobutyric acid type A receptor family (e.g.,
GABRA2, GABRA2, GABRA3, GABRA5) are the most targeted genes by clinically available drugs.
In addition, HCN channels which can generate hyperpolarization-activated cation currents and be a
causative gene for epilepsy, could also be a potential target tailored as an antiepileptic agent [21,22].
The defect in the KCNJ11 gene (Kir2-encoded current) can also cause convulsive disorder. The opener
of these channels could be tailored for a specific antiepileptic agent [23–25]. Our systematic approach
can be effectively applied to identify those causative genes as well as the potential drugs targeting them.
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drugs and their targ ts. (a) The x-axis represents th number of epilepsy causative genes arget d by
list d rugs. Note that Ethanol is top r ked drug ta geting 40 epilepsy causativ gene . L-Glutamic
acid and zonisamide are als top-ranked drugs; each of them targets 39 and 30 genes, respectively.
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by less than five drugs. (c) The x-axis represents the number of epilepsy-causative genes based on
GENECARD and the y-axis represents the number of drugs. For example, most of drugs (2209 drugs)
target less than five epilepsy-causative genes.
As shown in Figure 4b, most drugs (89%) target less than 5 epilepsy causative genes. Interestingly,
those top-ranked drugs report direct or indirect known associations with epilepsy. Zonisamide,
picrotoxin, triazolam, alprazolam, and lorazepam, especially, are identified as the drugs targeting at
least 20 epilepsy causative genes (Figure 4a). Such broad targeting of drugs may increase effectiveness;
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however, it may also cause severe unexpected side effects [26]. Therefore, recently developed
anti-epileptic drugs reveal a tendency toward targeting a small number of targets.
Also, among top-ranked drugs in Figure 4a, well-known drugs zonisamide and L-glutamic
acid [27,28] have critical roles for decreasing the seizures of patients suffering from uncontrolled
epilepsy. Meanwhile, most of the top-ranked drugs show the opposite role for epilepsy control by
target epilepsy-causative genes. For example, Picrotoxin [29] is used for relieving respiratory distress
but plays an important role in establishing GABA as an inhibitory transmitter and can cause seizures
by impacting the central nervous system. This side effect is easily predicted from our network, where
these drugs access many epilepsy-causative genes and it can cause such unexpected results. Similarly,
alprazolam and triazolam are also known to cause seizures occasionally although they are beneficial
for patients with major depression. Thus, we need to investigate with caution in interpreting the
results. Most of the top-ranked drugs in Figure 4 are identified as drugs causing epilepsy or seizure as
side effects, although they have a positive therapeutic effect on another disease. Thus, a target-based
drug repositioning strategy should not choose the drugs sharing targets with epilepsy-causative genes,
but consider the drug–target interaction types.
4. Discussion
In our EDT-drug network, we observed that the voltage-gated potassium channels associated
genes are located far from the targets of current AEDs. The voltage-gated potassium channels are
known to be one of the commonly perturbed mechanisms in intractable epilepsy patients. Indeed,
as shown in Figure 4, we could observe that the current 13 AEDs are not targeting any of the genes
associated with this biological process. Recently, there was a newly developed drug, Retigabine [30],
which was designed to target voltage-gated potassium channels. Retigabine was the first unique
potassium channel opener that worked by activating a part of KCNQ potassium channels in the
brain [15] and it was effective for intractable epilepsy patients having trouble in voltage-gated potassium
channels. However, there were reported adverse effects including blue skin discoloration and eye
abnormalities characterized by pigment changes in the retina [31]. Unfortunately, Retigabine was
recently discontinued due to the unexpected adverse effects. Although Retigabine was discontinued,
our observation shows a new promise for drug repositioning to recommend novel drugs for intractable
epilepsy patients.
In summary, we constructed the epilepsy drug-target network (EDT) and successfully
demonstrated the effectiveness of popularly used AEDs and the pathological mechanisms of existing
AEDs. Our study contributes to the identification of novel drug repositioning strategies through a
combination of the drug–target and functional networks.
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